Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

First of many Neuro-Biotech’s licensed products, “SymPath(R) blood test”

October 4, 2010 By Bio-Medicine.Org

BASEL, Switzerland, Oct. 4 /PRNewswire-FirstCall/ –
Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to
the company’s press release issued the 30th of September 2010, the
following is a brief review and explanation of the earlier
statements concerning the first of many Neuro-Biotech’s licensed
products, “SymPath(R) blood test”.

For a better understanding, an “in vitro” blood test is
described as, a non evasive test, whereas the testing, as in the
case of SymPath(R), is performed on a small amount of the patient’s
blood. To date the SymPath(R) blood test has been tested on several
thousand of patients whose results illustrate a success rate
accuracy of 98.8%. The testing audits have been rigorously
documented and have met every industry standard.

SymPath(R) is an indispensable tool with unprecedented results.
Medical practitioners have long been waiting for a similar test to
accurately and quantifiably diagnose those symptoms amongst
patients as, depression and stress related disorders. What does
this mean for physicians?

Firstly, SymPath(R) assists the medical practitioner in
diagnosing patients, based on quantitative measurement, as precise
as current cholesterol tests. SymPath(R) allows the medical
practitioner to determine with accuracy the severity level of the
patient’s anxiety or depressive state. The medical practitioner
will now be able to state, based on an objective quantified
measure, using this test, rather than subjectively determining the
diagnosis, as is currently performed.

Furthermore SymPath(R) will eliminate the costly and highly
inefficient trial and errors currently performed by physicians in
prescribing their recommended remedy, which can waste time and
further cause harm for both patients and physicians. For instance,
patients suffering from depression or stress related disorders will
now properly diagnosed immediately following the testing through
Neuro-Biotech’s SymPath(R) test.

No more g

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech